ANP32A and breast carcinoma: Interestingly, contrary to our results with TCGA, this independent cohort demonstrated a worst prognostic effect with increased expression of ANP32A (Fig. 8D and Additional file 1: Fig. S12, panel 9) and RPL13 (Fig. 8D and Additional file 1: Fig. S12, panel 1), demonstrating the heterogeneity of luminal-like breast cancers and the importance of a dual validation through independent cohorts when assessing survival curves.